Frexalimab study validates PROMIS-Fatigue-MS-8a and MSIS-29v2 in relapsing multiple sclerosis patients
New tools reliably measure fatigue in multiple sclerosis
This Phase 2 trial assessed psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 in adults with relapsing multiple sclerosis.
Two questionnaires accurately track fatigue in relapsing MS, offering a new way to measure treatment benefits in trials.
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
Could New Treatments Help Those Struggling with Kidney Disease?
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
New kidney treatments aim to reduce urine protein and improve daily life for patients with FSGS or minimal change disease.